EP0799231B1 - Spiroketalderivate, diese enthaltende zusammensetzungen und ihre verwendung als arzneimittel - Google Patents

Spiroketalderivate, diese enthaltende zusammensetzungen und ihre verwendung als arzneimittel Download PDF

Info

Publication number
EP0799231B1
EP0799231B1 EP95940382A EP95940382A EP0799231B1 EP 0799231 B1 EP0799231 B1 EP 0799231B1 EP 95940382 A EP95940382 A EP 95940382A EP 95940382 A EP95940382 A EP 95940382A EP 0799231 B1 EP0799231 B1 EP 0799231B1
Authority
EP
European Patent Office
Prior art keywords
compound
dioxa
aza
spiro
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95940382A
Other languages
English (en)
French (fr)
Other versions
EP0799231A1 (de
Inventor
Timothy Harrison
Simon Neil Owen
Eileen Mary Seward
Christopher John Swain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of EP0799231A1 publication Critical patent/EP0799231A1/de
Application granted granted Critical
Publication of EP0799231B1 publication Critical patent/EP0799231B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to a class of spiroketal compounds which are useful as tachykinin antagonists.
  • the present invention also relates to processes for their preparation, pharmaceutical compositions containing them, and to their use in therapy.
  • tachykinins are a group of naturally occurring peptides found widely distributed throughout mammalian tissues, both within the central nervous system and in peripheral nervous and circulatory systems.
  • the tachykinins are distinguished by a conserved carboxyl-terminal sequence:
  • tachykinins there are three known mammalian tachykinins referred to as substance P, neurokinin A (NKA, substance K, neuromedin L) and neurokinin B (NKB, neuromedin K) (for review see J.E. Maggio, Peptides (1985) 6 (suppl. 3), 237-242).
  • the current nomenclature designates the three tachykinin receptors mediating the biological actions of substance P, NKA and NKB as the NK 1 , NK 2 and NK 3 receptors, respectively.
  • tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, proliferative vitreoretinopathy, irritable bowel syndrome and disorders of bladder function including cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R. Patacchini, P. Rovero and A. Giachetti, J. Auton. Pharmacol. (1993) 13 , 23-93.
  • substance P is believed inter alia to be involved in the neurotransmission of pain sensations [Otsuka et al, "Role of Substance P as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia” in 1982 Substance P in the Nervous System, Ciba Foundation Symposium 91, 13-34 (published by Pitman) and Otsuka and Yanagisawa, "Does Substance P Act as a Pain Transmitter?" TIPS (1987) 8 , 506-510], specifically in the transmission of pain in migraine (B.E.B. Sandberg et al, J. Med Chem, (1982) 25 , 1009) and in arthritis [Levine et al Science (1984) 226 , 547-549].
  • Tachykinins have also been implicated in gastrointestinal (GI) disorders and diseases of the GI tract such as inflammatory bowel disease [Mantyh et al Neuroscience (1988) 25 (3), 817-37 and D. Regoli in “Trends in Cluster Headache” Ed. Sicuteri et al Elsevier Scientific Publishers, Amsterdam (1987) page 85)] and emesis [F. D. Tattersall et al, Eur. J. Pharmacol., (1993) 250 , R5-R6].
  • GI gastrointestinal
  • tachykinin antagonists are believed to be useful are allergic conditions [Hamelet et al, Can. J. Pharmacol. Physiol. (1988) 66 , 1361-7], immunoregulation [Lotz et al, Science (1988) 241, 1218-21 and Kimball et al, J. Immunol.
  • Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon et al, Cancer Research (1992) 52 , 4554-7].
  • SCLC small cell lung cancer
  • Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Luber-Narod et al, poster C.I.N.P. XVIIIth Congress, 28th June-2nd July 1992], and in disorders of bladder function such as bladder detrusor hyper-reflexia (Lancet, 16th May 1992, 1239).
  • demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Luber-Narod et al, poster C.I.N.P. XVIIIth Congress, 28th June-2nd July 1992]
  • disorders of bladder function such as bladder detrusor hyper-reflexia (Lancet, 16th May 1992, 1239).
  • tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosus (European patent specification no. 0 436 334), ophthalmic disease such as conjuctivitis.
  • European patent specification no. 0 577 394 discloses morpholine and thiomorpholine tachykinin receptor antagonists of the general formula
  • the present invention provides compounds of the formula (I): wherein
  • a preferred class of compound of formula (I) is that wherein R 1 represents hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, C 1-6 alkoxy, C 1-4 alkyl substituted by a C 1-4 alkoxy group, OCF 3 , hydroxy, trifluoromethyl, trimethylsilyl, nitro, CN, SR a , SOR a , SO 2 R a , COR a , CO 2 R a , CONR a R b where R a and R b are each independently hydrogen or C 1-4 alkyl; and R 2 and R 3 each independently represent hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy substituted by C 1-4 alkoxy or trifluoromethyl.
  • Certain particularly apt compounds of the present invention include those wherein R 1 is hydrogen, C 1-4 alkyl, C 1-4 alkoxy, halo or CF 3 .
  • R 2 is hydrogen, C 1-4 alkyl, C 1-4 alkoxy, halogen or CF 3 .
  • R 3 is hydrogen, fluorine, chlorine or CF 3 .
  • R 1 is C 1-4 alkoxy, especially methoxy, ethoxy, n-propoxy, i-propoxy or t-butoxy.
  • R 2 is hydrogen, fluorine, chlorine or C 1-4 alkyl, especially hydrogen, fluorine, i-propyl, or t-butyl.
  • R 3 is hydrogen
  • R 1 is in the 2-position on the phenyl ring.
  • R 2 is in the 5-position on the phenyl ring.
  • R 4 is hydrogen
  • R 5 is hydrogen, fluorine, chlorine or CF 3 .
  • R 4 is hydrogen and R 5 is hydrogen or 4-fluoro.
  • R 9a and R 9b are each independently hydrogen or methyl.
  • R 9a is hydrogen.
  • R 9b is hydrogen.
  • R 9a and R 9b are both hydrogen.
  • n 1
  • n is 1 or 2, especially 1.
  • R 6 is C 1-6 alkyl, in particular CH 2 , CH(CH 3 ) and CH 2 CH 2 and especially CH 2 , substituted by a 5-membered ring.
  • the 5-membered ring is a heterocyclic ring selected from:
  • heterocyclic rings are selected from:
  • heterocyclic ring is selected from:
  • a particularly preferred heterocyclic ring is:
  • R 1 , R 2 , R 3 , R 4 , R 5 , m and n are as defined in relation to formula (I) and Q 1 is CH, N or C-ZNR 7 R 8 wherein Z, R 7 and R 8 are as defined in relation to formula (I).
  • a further favoured group of compounds of the present invention are of the formula (Ic) and pharmaceutically acceptable salts thereof: wherein
  • a 1 is preferably methoxy, ethoxy, n-propoxy or i-propoxy.
  • a 2 is hydrogen, fluorine or trifluoromethyl.
  • a 3 is hydrogen or fluorine.
  • Z may be a linear, branched or cyclic group.
  • Favourably Z contains 1 to 4 carbon atoms and most favourably 1 or 2 carbon atoms.
  • a particularly favourable group Z is CH 2 .
  • R 7 may aptly be a C 1-4 alkyl group or a C 2-4 alkyl group substituted by a hydroxyl or C 1-2 alkoxy group
  • R 8 may aptly be a C 1-4 alkyl group or a C 1-4 alkyl group substituted by a hydroxyl or C 1-2 alkoxy group
  • R 7 and R 8 may be linked so that, together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl, piperidyl, morpholino.
  • group NR 7 R 8 represents a heteroaliphatic ring of 4 to 7 ring atoms and said ring contains a double bond
  • a particularly preferred group is 3-pyrroline
  • group NR 7 R 8 represents a non-aromatic azabicyclic ring system
  • such a system may contain between 6 and 12, and preferably between 7 and 10, ring atoms.
  • Suitable rings include 5-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.2.1]heptyl, 6-azabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.2]octyl, 6-azabicyclo[3.2.2]nonyl, 6-azabicyclo[3.3.1]nonyl, 6-azabicyclo[3.2.2]decyl, 7-azabicyclo[4.3.1]decyl, 7-azabicyclo[4.4.1]undecyl and 8-azabicyclo[5.4.1]dodecyl, especially 5-azabicyclo[2.2.1]heptyl and 6-azabicyclo[3.2.1]octyl.
  • R 8 represents a C 2-4 alkyl group substituted by a 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S
  • suitable rings include pyrrolidino, piperidino, piperazino, morpholino, or thiomorpholino.
  • Particularly preferred are nitrogen containing heteroaliphatic rings, especially pyrrolidino and morpholino rings.
  • moieties ZNR 7 R 8 include those wherein Z is CH 2 or CH 2 CH 2 and NR 7 R 8 is amino, methylamino, dimethylamino, diethylamino, azetidinyl, pyrrolidino and morpholino.
  • ZNR 7 R 8 Further preferred moieties represented by ZNR 7 R 8 are those wherein Z is CH 2 or CH 2 CH 2 , R 7 represents hydrogen, C 1-4 alkyl or C 3-6 cycloalkyl and R 8 is C 2-4 alkyl substituted by one or two substituents selected from hydroxy, C 1-2 alkoxy, azetidinyl, pyrrolidino, piperidino, morpholino or thiomorpholino.
  • Z is preferably CH 2 and NR 7 R 8 is preferably dimethylamino, azetidinyl or pyrrolidino, especially dimethylamino.
  • R 1 and R 2 together with the carbon atoms to which they are attached, form a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms selected from oxygen, sulfur or nitrogen, or 1 or 2 groups selected from S(O), S(O) 2 and NR a , and which ring may also contain 1 or 2 double bonds, it will be appreciated that the ring thus formed may be saturated, partially saturated or unsaturated.
  • R a preferably represents a hydrogen atom.
  • alkyl or "alkoxy" as a group or part of a group means that the group is straight or branched.
  • suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.
  • cycloalkyl groups referred to herein may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • a suitable cycloalkylalkyl group may be, for example, cyclopropylmethyl.
  • alkenyl and “alkynyl” as a group or part of a group means that the group is straight or branched.
  • suitable alkenyl groups include vinyl and allyl.
  • a suitable alkynyl group is propargyl.
  • fluoroC 1-6 alkyl and “fluoroC 1-6 alkoxy” means a C 1-6 alkyl or C 1-6 alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by a fluorine atom.
  • fluoroC 1-3 alkyl and fluoroC 1-3 alkoxy groups for example, CF 3 , CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 , OCF 3 , OCH 2 CH 2 F, OCH 2 CHF 2 or OCH 2 CF 3 , and most especially CF 3 and OCF 3 .
  • halogen means fluorine, chlorine, bromine and iodine.
  • the most apt halogens are fluorine and chlorine of which fluorine is preferred.
  • the compounds of formula (I) will preferably be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.
  • the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts.
  • Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid.
  • Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety.
  • suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.
  • the salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.
  • the present invention includes within its scope prodrugs of the compounds of formula (I) above.
  • prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I).
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • a prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug” or “parent molecule”) that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule.
  • the transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.
  • the present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.
  • the compounds according to the invention have at least three asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • the present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in association with a pharmaceutically acceptable carrier or excipient.
  • compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.
  • the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.
  • a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water
  • a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium
  • This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
  • compositions for administration by injection include those comprising a compound of formula (I), as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).
  • a surface-active agent or wetting agent or surfactant
  • an emulsion as a water-in-oil or oil-in-water emulsion
  • Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g. TweenTM 20, 40, 60, 80 or 85) and other sorbitans (e.g. SpanTM 20, 40, 60, 80 or 85).
  • Compositions with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
  • Suitable emulsions may be prepared using commercially available fat emulsions, such as IntralipidTM, LiposynTM, InfonutrolTM, LipofundinTM and LipiphysanTM.
  • the active ingredient may be either dissolved in a premixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. egg phospholipids, soybean phospholipids or soybean lecithin) and water.
  • an oil e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil
  • a phospholipid e.g. egg phospholipids, soybean phospholipids or soybean lecithin
  • other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion.
  • Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%.
  • the fat emulsion will preferably comprise fat droplets between 0.1 and 1.0 ⁇ m, particularly 0.1 and 0.5 ⁇ m, and have a pH in the range of 5.5 to 8.0.
  • Particularly preferred emulsion compositions are those prepared by mixing a compound of formula (I) with IntralipidTM or the components thereof (soybean oil, egg phospholipids, glycerol and water).
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine.
  • Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
  • the present invention futher provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), which process comprises bringing a compound of formula (I) into association with a pharmaceutically acceptable carrier or excipient.
  • the compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity.
  • an excess of tachykinin, and in particular substance P, activity is implicated in a variety of disorders of the central nervous system.
  • disorders include mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders and psychotic disorders with delusions or hallucinations; delerium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Alzheimer's disease
  • Tachykinin, and in particular substance P, activity is also involved in nociception and pain.
  • the compounds of the present invention will therefore be of use in the prevention or treatment of diseases and conditions in which pain predominates, including soft tissue and peripheral damage, such as acute trauma, osteoarthritis, rheumatoid arthritis, musculo-skeletal pain, particularly after trauma, spinal pain, myofascial pain syndromes, headache, episiotomy pain, and burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, and labour pain; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis
  • Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of respiratory diseases, particularly those associated with excess mucus secretion, such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis and asthma, adult respiratory distress syndrome, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis, pruritis and sunburn; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis.
  • respiratory diseases
  • Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of neoplasms, including breast tumours, neuroganglioblastomas and small cell carcinomas such as small cell lung cancer.
  • Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of gastrointestinal (GI) disorders, including inflammatory disorders and diseases of the GI tract such as gastritis, gastroduodenal ulcers, gastric carcinomas, gastric lymphomas, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis, including acute, delayed or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, for example, motion sickness, vertigo, dizziness and Meniere's disease, surgery, migraine, variations in intercranial pressure, gastro-oesophageal reflux disease, acid indigestion, over indulgence in food or drink, acid stomach, waterbrash or regurgitation, heartburn, for example, episodic, nocturnal or meal-induced heartburn, and dyspepsia.
  • GI gastrointestinal
  • GI gastrointestinal
  • GI
  • Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of a variety of other conditions including stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; plasma extravasation resulting from cytokine chemotherapy, disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease; and pain or nociception attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.
  • stress related somatic disorders such as shoulder/hand syndrome
  • adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune
  • the compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.
  • the compounds of formula (I) are particularly useful in the treatment of emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intercranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis induced by antineoplastic (cytotoxic) agents including those routinely used in cancer chemotherapy.
  • antineoplastic (cytotoxic) agents including those routinely used in cancer chemotherapy.
  • chemotherapeutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophyllotoxin; and cytotoxic antibiotics.
  • alkylating agents for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine
  • antimetabolites for example, folic acid, purine or pyrimidine antagonists
  • mitotic inhibitors for example, vinca alkaloids and derivatives of podophyllotoxin
  • cytotoxic antibiotics include cytotoxic antibiotics.
  • chemotherapeutic agents are described, for instance, by D. J. Stewart in Nausea and Vomiting: Recent Research and Clinical Advances, Eds. J. Kucharczyk et al, CRC Press Inc., Boca Raton, Florida, USA (1991) pages 177-203, especially page 188.
  • chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla et al in Cancer Treatment Reports (1984) 68 (1), 163-172].
  • the compounds of formula (I) are also of use in the treatment of emesis induced by radiation including radiation therapy such as in the treatment of cancer, or radiation sickness; and in the treatment of post-operative nausea and vomiting.
  • the compounds of formula (I) may be presented together with another therapeutic agent as a combined preparation for simultaneous, separate or sequential use for the relief of emesis.
  • Such combined preparations may be, for example, in the form of a twin pack.
  • a further aspect of the present invention comprises the compounds of formula (I) in combination with a 5-HT 3 antagonist, such as ondansetron, granisetron or tropisetron, or other anti-emetic medicaments, for example, a dopamine antagonist such as metoclopramide.
  • a compound of formula (I) may be administered in combination with an anti-inflammatory corticosteroid, such as dexamethasone.
  • a compound of formula (I) may be administered in combination with a chemotherapeutic agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above.
  • a chemotherapeutic agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above.
  • the currently available dosage forms of the known therapeutic agents for use in such combinations will be suitable.
  • the compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteroarthritis, rheumatoid arthritis and headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain.
  • neuropathy such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteroarthritis, rheumatoid arthritis and headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain.
  • the present invention further provides a compound of formula (I) for use in therapy.
  • the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.
  • the present invention also provides a method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).
  • a compound according to the present invention for the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically active agent.
  • a compound of formula (I) may be used in conjunction with a bronchodilator, such as a ⁇ 2 -adrenergic receptor antagonist or tachykinin antagonist which acts at NK-2 receptors.
  • the compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.
  • a compound of the present invention may be employed with a leukotriene antagonists, such as a leukotriene D 4 antagonist such as a compound selected from those disclosed in European patent specification nos. 0 480 717 and 0 604 114 and in US patent nos. 4,859,692 and 5,270,324.
  • a leukotriene D 4 antagonist such as a compound selected from those disclosed in European patent specification nos. 0 480 717 and 0 604 114 and in US patent nos. 4,859,692 and 5,270,324.
  • This combination is particularly useful in the treatment of respiratory diseases such as asthma, chronic bronchitis and cough.
  • the present invention accordingly provides a method for the treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.
  • the present invention also provides a composition
  • a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.
  • a compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-HT 1 agonists, especially sumatriptan.
  • a compound of the present invention may be used in conjunction with an antagonist of N-methyl D-aspartate (NMDA), such as dizocilpine.
  • NMDA N-methyl D-aspartate
  • a compound of the present invention may be used in conjunction with an anti-inflammatory agent such as a bradykinin receptor antagonist.
  • the present invention also provides a composition
  • a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.
  • a compound of the present invention may be used in conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs and, in particular, opioid analgesics, especially morphine.
  • analgesics such as acetaminophen (paracetamol), aspirin and other NSAIDs and, in particular, opioid analgesics, especially morphine.
  • opioid analgesics especially morphine.
  • Specific anti-inflammatory agents include diclofenac, ibuprofen, indomethacin, ketoprofen, naproxen, piroxicam and sulindac.
  • Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof.
  • Preferred salts of these opioid analgesics include morphine sulphate, morphine hydrochloride, morphine tartrate, codeine phosphate, codeine sulphate, dihydrocodeine bitartrate, diacetylmorphine hydrochloride, hydrocodone bitartrate, hydromorphone hydrochloride, levorphanol tartrate, oxymorphone hydrochloride, alfentanil hydrochloride, buprenorphine hydrochloride, butorphanol tartrate, fentanyl citrate, meperidine hydrochloride, methadone hydrochloride, nalbuphine hydrochloride, propoxyphene hydrochloride, propoxyphene napsylate (2-naphthalenesulphonic acid (1:1) monohydrate), and pentazocine hydrochloride.
  • a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient.
  • a product comprising a compound of the present invention and an analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of pain or nociception.
  • the excellent pharmacological profile of the compounds of the present invention offers the opportunity for their use in therapy at low doses thereby minimising the risk of unwanted side effects.
  • a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.
  • a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 1 mg/kg per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • the compounds according to the invention may be prepared from a compound of formula (I) in which R 6 is H, hereinafter referred to as compounds of formula (II) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 9a , R 9b , m and n are as defined in relation to formula (I) by reaction with a compound of formula (III): LG-R 6a where R 6a is a group of the formula R 6 as defined in relation to formula (I) or a precursor therefor and LG is a leaving group such as an alkyl- or arylsulphonyloxy group (e.g.
  • R 6a is a precursor group, converting it to a group R b (in which process any reactive group may be protected and thereafter deprotected if desired).
  • This reaction may be performed in conventional manner, for example in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate.
  • compounds of formula (I) wherein R 6 represents a 1,2,3-triazol-4-ylmethyl group substituted by CH 2 NR 7 R 8 may be prepared by reaction of a compound of formula (IV) with an amine of formula NHR 7 R 8 , in a suitable solvent such as an ether, for example, dioxan, at elevated temperature, for example, between 50°C and 100°C, in a sealed tube, or the like.
  • a suitable solvent such as an ether, for example, dioxan
  • compounds of formula (I) wherein R 6 represents a C 1-6 alkyl group which is substituted by an unsubstituted or substituted 1,2,4-triazolyl group may be prepared by reaction of an intermediate of formula (II) with a compound of formula (V) wherein Hal is a halogen atom, for example, bromine, chlorine or iodine, m is an integer from 1 to 6 and R 18 is H, CONH 2 or OCH 3 (which is converted to an oxo substituent under the reaction conditions), in the presence of a base, followed where necessary by conversion to a compound of formula (I), for example, by reduction of the CONH 2 group to CH 2 NH 2 .
  • Hal is a halogen atom, for example, bromine, chlorine or iodine
  • m is an integer from 1 to 6
  • R 18 is H, CONH 2 or OCH 3 (which is converted to an oxo substituent under the reaction conditions)
  • Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate.
  • the reaction is conveniently effected in an anhydrous organic solvent such as, for example, anhydrous dimethylformamide, preferably at elevated temperature, such as about 140°C.
  • a suitable reducing agent for the group CONH 2 is lithium aluminium hydride, used at between -10°C and room temperature.
  • compounds of formula (I) may be prepared from intermediates of formula (VI) by an acid catalysed intramolecular cyclisation reaction.
  • Suitable acids of use in the reaction include mineral acids such as, for example, hydrochloric acid.
  • the reaction is conveniently effected in a suitable organic solvent, such as alcohol, e.g. methanol, at elevated temperature, for example, at the reflux temperature of the chosen solvent.
  • compounds of formula (I) may also be prepared from other compounds of formula (I) using suitable interconversion procedures.
  • interconversion processes may be used to vary the group R 6 .
  • compounds of formula (I) wherein R 6 is other than H may be prepared from the corresponding compounds of formula (I) wherein R 6 is H by reaction with a reagent suitable to introduce the group R 6
  • compounds of formula (I) wherein R 6 is COR a may be prepared from compounds of formula (I) wherein R 6 is H by, for example, reaction with an appropriate acid anhydride.
  • R 6 is C 1-6 alkyl
  • R 6 is COR a by reduction using, for example, borane or a borohydride such as sodium cyanoborohydride.
  • Compounds of formula (I) wherein R 6 is C 1-6 alkyl substituted by 5-oxadiazolyl may be prepared from compounds of formula (I) wherein R 6 is C 1-6 alkyl substituted by CO 2 R a , where R a represents C 1-6 alkyl, by reaction with a compound of formula (VII) wherein R 32 represents H or a suitable substituent, in the presence of a base.
  • Suitable bases of use in the reaction include alkali metals, such as, for example, sodium, and alkali metal hydrides, such as, for example, sodium hydride.
  • reaction is conveniently effected in a suitable organic solvent.
  • suitable solvents will include alcohols, for example, ethanol, whereas where the base used is an alkali hydride, suitable solvents will include ethers, for example, tetrahydrofuran.
  • reaction is conducted at elevated temperature, such as the reflux temperature of the chosen solvent.
  • Compounds of formula (I) wherein R 6 is C 1-6 alkyl substituted by thiazolyl may be prepared from compounds of formula (I) wherein R 6 is C 1-6 alkyl substituted by CSNH 2 by reaction with a compound of formula Hal-CH 2 C(O)-R 60 , where Hal is a halogen atom, such as bromine, chlorine or iodine, and R 60 represents H or a suitable substituent.
  • Compounds of formula (I) wherein R 6 is C 1-6 alkyl substituted by thioxotriazolyl may be prepared from compounds of formula (I) wherein R 6 is C 1-6 alkyl substituted by CONHNH 2 by reaction with a compound of formula R 61 NCS, wherein R 61 represents H or a suitable substituent such as C 1-6 alkyl, in the presence of a base.
  • Suitable bases of use in the reaction include organic bases such as, for example, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
  • DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
  • the reaction is conveniently effected in a suitable organic solvent, such as alcohol, e.g. butanol.
  • Suitable reducing conditions include: catalytic hydrogenation using a metal catalyst such as palladium or platinum or hydroxides or oxides thereof, preferably in a suitable solvent such as alcohol, e.g. methanol or ethanol, or an ester, e.g. ethyl acetate, or an organic acid e.g. acetic acid, or a mixture thereof; borane in tetrahydrofuran; 9-boracyclo[3.3.1]nonane (9-BBN) in an ether such as tetrahydrofuran; and lithium triethylborohydride (Super-HydrideTM) in an ether such as tetrahydrofuran.
  • a metal catalyst such as palladium or platinum or hydroxides or oxides thereof
  • a suitable solvent such as alcohol, e.g. methanol or ethanol, or an ester, e.g. ethyl acetate, or an organic acid e.g. acetic acid, or
  • Intermediates of formula (IV) may be prepared from a compound of formula (VIII) wherein Hal is a halogen atom, for example, chlorine, bromine or iodine, especially chlorine, by reaction with an azide, for example, sodium azide in a suitable solvent such as dimethylsulphoxide at or below room temperature.
  • Hal is a halogen atom, for example, chlorine, bromine or iodine, especially chlorine
  • an azide for example, sodium azide in a suitable solvent such as dimethylsulphoxide at or below room temperature.
  • Compounds of formula (VIII) may be prepared by a dropwise addition of an intermediate of formula (II) to a dihaloacetylene of formula Hal-CH 2 -C ⁇ C-CH 2 -Hal where each Hal is independently chlorine, bromine or iodine, especially chlorine.
  • the reaction is conveniently effected in a suitable solvent such as dimethylformamide in the presence of a base such as potassium carbonate.
  • Intermediates of formula (VI) wherein m is 2 may be prepared by the reduction of a compound of formula (IX): or a protected derivative thereof, using conventional methodology, for instance, by catalytic hydrogenation using a metal catalyst such as palladium or platinum or oxides thereof. preferably in a solvent such as an alcohol, e.g. ethanol, or an ester, e.g. ethyl acetate.
  • a metal catalyst such as palladium or platinum or oxides thereof.
  • a solvent such as an alcohol, e.g. ethanol, or an ester, e.g. ethyl acetate.
  • Compounds of formula (IX) may be prepared by the reaction of a compound of formula (X): with a compound of formula (XI): or a protected derivative thereof, by lithiation using n-butyl lithium followed by quenching with. for example. sodium dihydrogen orthophosphate.
  • the reaction is conveniently effected in a solvent such as an ether, e.g. tetrahydrofuran, at reduced temperature, for example, at -78°C.
  • R 6 is a C 1-6 alkyl group substituted by a 5-membered heterocycle which in turn is substituted by a ZNR 7 R 8 group where Z is CH 2
  • certain favoured compounds of formula (I) may be prepared from a corresponding compound with a hydrogen atom in place of the ZNR 7 R 8 .
  • a compound of the formula (I) wherein R 6 is an imidazolinone group carrying a CH 2 NR 7 R 8 moiety may be prepared from a corresponding compound lacking the CH 2 NR 7 R 8 moiety by reaction with formaldehyde and an amine NHR 7 R 8 under conventional Mannich reaction conditions, for example in methanol with heating.
  • a compound of formula (I) wherein R 6 is a C 1-6 alkyl group substituted by an imidazolinone group may be reacted with paraformaldehyde and an amine for example a secondary amine such as pyrrolidine or morpholine to give a compound wherein the imidazolinone ring is substituted by CH 2 NR 7 R 8 where R 7 , R 8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom or a second nitrogen atom which will be part of a NH or NR c moiety, where R c is as previously defined.
  • This reaction may be performed in a conventional manner, for instance, in a suitable solvent such as an alcohol, for example, methanol at an elevated temperature up to the boiling point of the solvent.
  • a suitable solvent such as an alcohol, for example, methanol
  • a further alternative method for the preparation of certain compounds of formula (I) involves the reaction of an intermediate of formula (II) as defined above with one of the compounds of formula (XII): wherein each LG, which may be the same or different, is a leaving group, such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or, in particular, a halogen atom, (e.g. bromine, chlorine or iodine), m is an integer from 1 to 6 and X and Z are as defined in formula (I), followed by reaction of the resultant compound with an amine NHR 7 R 8 to complete the ZNR 7 R 8 moiety.
  • each LG which may be the same or different, is a leaving group, such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or, in particular, a halogen atom, (e.g. bromine, chlorine or iodine),
  • This reaction is conveniently effected in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate.
  • Compounds of formula (XX) may be prepared by the reaction of a compound of formula (XXI): wherein R 30 is a suitable leaving group such as -OSO 2 CF 3 , with a boronic acid of formula (XXII): or an ester or an anhydride thereof.
  • the reaction is preferably effected in the presence of a transition metal catalyst such as tetrakis(triphenylphosphine)palladium (0) in a suitable solvent such as an ether, for example, tetrahydrofuran or 1,2-dimethoxyethane, in the presence or absence of water, or an aromatic hydrocarbon, for example, benzene.
  • a transition metal catalyst such as tetrakis(triphenylphosphine)palladium (0)
  • a suitable solvent such as an ether, for example, tetrahydrofuran or 1,2-dimethoxyethane
  • an aromatic hydrocarbon for example, benzene.
  • the reaction is preferably effected in the presence of a base such as an alkali or alkaline earth metal carbonate, for example, sodium carbonate, at a suitable temperature up to reflux.
  • compounds of formula (XX) may be prepared by the reaction of a compound of formula (XXIV) wherein each R 40 is a C 1-4 alkyl group, preferably methyl groups, with a compound of formula (XXV) wherein Hal is a halogen atom, for example, chlorine, bromine or iodine, especially bromine.
  • the reaction is conveniently effected in the presence of lithium chloride and a transition metal catalyst such as triphenylphosphine palladium(0).
  • Suitable solvents for the reaction include aromatic hydrocarbons, for example, toluene, the reaction being effected at a temperature between 80°C and the reflux temperature of the solvent.
  • Compounds of formula (XXIV) may be prepared from a corresponding compound of formula (XXI) by reaction with a compound of the formula (R 40 ) 3 Sn-Sn(R 40 ) 3 , for example, hexamethyl distannane.
  • the reaction is conveniently effected in the presence of a base, for example, lithium carbonate, and a catalyst such as triphenylphosphine palladium(0).
  • Suitable solvents for the reaction include ethers. such as tetrahydrofuran, the reaction being effected at a temperature between room temperature and 100°C, for example, at about 60°C.
  • Compounds of formula (XXI) may be prepared from a compound of formula (XXIII): by enolisation of the ketone in the presence of a base, for example, sodium hexamethyldisilazide, followed by reaction with a reagent capable of introducing a suitable leaving group, for instance, where R 30 is -OSO 2 CF 3 , using 2-[N,N-bis(trifluoromethylsulphonyl)amino]-5-chloropyridine or triflic anhydride.
  • the reaction is conveniently effected in a suitable solvent such as an ether, for example, tetrahydrofuran at a reduced temperature, for instance, -78°C.
  • R 6 is a benzyl group.
  • the reduction reaction described as process (G) above for the preparation of compounds of formula (XX) may conveniently replace the benzyl group with a hydrogen atom. It will be appreciated from the discussion above that compounds of formula (I) wherein R 6 is a hydrogen atom are particularly preferred precursors to other compounds of formula (I).
  • any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • the exemplified compounds of this invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No. WO 93/01165.
  • the compounds or. in the case of prodrugs, the parent compounds, were found to be active with IC 50 at the NK 1 receptor of less than 1 ⁇ M on said test method.
  • the alkene of Description 10 (18.9g, 57.7mmol) was stirred with osmium tetroxide (0.2g, 0.8mmol) and N-methylmorpholine N-oxide (7.78g, 66.4mmol) in a solution of tetrahydrofuran (200ml), 2-methyl-2-propanol (120ml) and water (14ml) for 3 days at room temperature.
  • the resulting black solution was diluted with ethyl acetate (200ml), water (200ml) and saturated brine (100ml), separated and the organic fraction dried (MgSO 4 ) and concentrated in vacuo.
  • triols of Description 11 (15.0g, 41.5mmol) was dissolved in hydrochloric acid (200ml, 6M), and methanol (100ml) and heated at reflux for 5 hours. The cooled solution was basified with 4N sodium hydroxide solution and extracted with ethyl acetate (3x200ml). The combined organic extracts were dried (MgSO 4 ) and concentrated in vacuo . The resulting black oil (18g) was purified by flash silica gel chromatography eluting with 33-66% ethyl acetate in hexane to yield the title compounds as pairs of diasteromers.
  • Triethylamine (13.3ml, 95.5mmol) was added dropwise over 10 minutes. and the reaction allowed to warm to room temperature. The resulting mixture was washed with dilute sodium bicarbonate solution (0.2M) and water (200ml) and the organic fraction dried (MgSO 4 ) and concentrated i n vacuo (7.9g). The crude product was purified by flash silica gel chromatography eluting with 14-20% ethyl acetate in hexane to yield the title compound as a pale yellow glass which solidified to a buff coloured solid on standing (5.2 g, 80%). Analysis: C 20 H 20 FNO 3 requires C, 70.37; H.
  • the ketone of Description 13 (4.0g, 11.7mmol) as a solution in anhydrous tetrahydrofuran (16ml) was added dropwise over 10 mintes to a solution of sodium bis(trimethylsilyl)amide (14.0ml of 1.0M solution in tetrahydrofuran; 14.0mmol) cooled to below -70°C.
  • the reaction mixture was stirred at this temperature for 2 hours before the addition of 2-[ N,N -bis(trifluoromethylsulphonyl)amino]-5-chloropyridine (6.44g, 16.4mmol) in several portions.
  • the solution was stirred at below -70°C for 1 ⁇ 2 hour before being allowed to warm to room temperature overnight.
  • n -Butyl lithium 13.0ml of a 1.6M solution in hexanes, 19.8mmol was added dropwise to a solution of 2-bromoanisole (3.74g, 19.0mmol) in anhydrous tetrahydrofuran (15ml) cooled to below -70°C, maintaining the temperature during the addition below -60°C.
  • the solution was stirred for 20 minutes before the addition of trimethyl borate (5.9ml, 57.0mmol), and then stirred at below -70°C for a further hour before warming to room temperature overnight.
  • reaction mixture was cooled to 0°C acidified to pH 5.0 with 5% aqueous hydrochloric acid solution (25ml), the resulting layers separated and the aqueous phase extracted with ethyl acetate (2x25ml).
  • the combined orgnic layers were washed with brine (25ml), dried (MgSO 4 ) and concentrated in vacuo to yield the title compound as a white solid (2.9g, 97%) which was used without further purification.
  • ⁇ , ⁇ , ⁇ -trifluoro- o -tolualdehyde (3g) was dissolved in anhydrous tetrahydrofuran and cooled to -78°C, iodochloromethane (1.38ml) was then added, followed by methyllithium (1.5M complexed with lithium bromide) (12ml) added over 5 minutes. The reaction was left to warm up to room temperature overnight. The reaction was quenched using saturated ammonium chloride solution and extracted using diethyl ether (2x50ml). The combined organic extracts were washed with brine, dried (MgSO 4 ) and concentrated to afford a brown oil.
  • the second fraction to elute from the column described in Example 1 comprised a 1:1 mixture of isomers, inseparable by chromatography. The mixture was separated by fractional crystallisation from isopropanol to afford the title compound as colourless needles. MS CI + m/z 400 (M+1 + , 100%).
  • Example 1 The product of Example 1 (Isomer A) (0.2g) was dissolved in ethyl acetate with HCl (50ml), wetted palladium on carbon (20%) (120mg) was added and the reaction placed under an atmosphere of hydrogen, 40psi. When TLC (20% ethyl acetate in petrol) showed no starting material the catalyst was removed in vacuo. The resultant yellow oil was purified on flash silica eluted with 20% ethyl acetate in petrol going up to 10% methanol in ethyl acetate to afford the title compound. MS CI + m/z 310 (M+1 + , 100%).
  • Example 2 The product of Example 2 (Isomer B1) (0.44g) was dissolved in methanolic ethyl acetate, wetted palladium on carbon (10%) (0.2g) was added and the reaction put under an atmosphere of hydrogen 40psi overnight. The catalyst was removed by filtration to afford the title compound as a white crystalline solid upon evaporation. MS CI + m/z 310 (M+1 + , 100%).
  • Example 6 The compound of Example 6 (0.25g) was suspended in N,N'-dimethylformamide (2.6ml) with potassium carbonate (0.3g) and N-methylcarboxy-2-chloroacetamidrazone (see EP-0577394-A) (0.134g) and heated at 70°C for one hour. The dark yellow mixture was heated to 140°C to effect cyclisation. TLC in 5% methanol in ethyl acetate showed a good separation between the starting material. the acyclic and cyclic products. The mixture was diluted with water (30ml) and ethyl acetate (10ml).
  • the enol triflate of Description 14 (240mg, 0.51mmol) was dissolved in anhydrous 1,2-dimethoxyethane (1.75ml) under an inert atmosphere.
  • Sodium bicarbonate solution (0.76ml of a 2.0M solution, 1.52mmol) was added followed by phenylboronic acid (87mg, 0.71mmol), lithium chloride (64mg, 1.52mmol) and tetrakis(triphenylphosphine)palladium (0) (29mg, 0.025mmol) and the resulting mixture heated at reflux for 11 ⁇ 2hours.
  • the reaction mixture was concentrated in vacuo and the residue partitioned between ethyl acetate (20ml) and water (20ml).
  • step (a) The alkene of step (a) (90mg, 0.22mmol) was hydrogenated overnight at 40psi in methanol (15ml) and chloroform (16 ⁇ l) over 10% palladium on charcoal (0.15g). The catalyst was removed by filtration through a pad of HyfloTM, and the solvent evaporated. The residue was partitioned between dilute sodium bicarbonate (20ml) and ethyl acetate (20ml) and the combined organic extracts dried (MgSO 4 ) and concentrated in vacuo. Further purification by flash silica gel chromatography eluting with 50-100% ethyl acetate in hexane, afforded the title compound as a colourless oil (61mg, 87%).
  • step (a) The alkene of step (a) (200mg, 0.46mmol) was dissolved in warm methanol (5ml) and degassed with nitrogen for 5-10 minutes. Ammonium formate (500mg) and 10% palladium on charcoal (100mg) were added, the reaction flask purged with nitrogen, and the resulting suspension heated at reflux for 2-24 hours. The cooled reaction mixture was filtered through a pad of HyfloTM, and concentrated in vacuo to a crude gum which was purified by flash silica gel chromatography eluting with 67-100% ethyl acetate in hexane (or 4-8% methanol in dichloromethane) to yield the title compound as a colourless oil (80mg, 51%).
  • the diol of Description 18 (2.4g, 5.7mmol) was heated at reflux in a solution of 6N hydrochloric acid (127ml) and methanol (38ml) for 18 hours. The methanol was evaporated in vacuo and the aqueous residue neutralised to pH 7-8 with sodium carbonate. The resulting solution was extracted with ethyl acetate (3x200ml), the combined organic extracts dried (MgSO 4 ) and concentrated in vacuo to an orange oil (3.0g). The crude concentrate was purified by flash silica gel chromatography eluting with 8-20% ethyl acetate in hexane to yield the separated title compounds as viscous oils which solidified on standing (1.05g total, 46%).
  • Example 12 Isomer A of Example 12 (303mg, 0.75mmol) was dissolved in methanol (15ml) and chloroform (2 ⁇ l, 0.25mmol), and hydrogenated at 40psi with 10% palladium on charcoal (200mg) for 4 hours. The solution was filtered through a pad of HyfloTM, concentrated to dryness in vacuo and the residual solid (234mg) recrystallised to give the title compound as a white solid (100mg). m.p. 260-261°C (dec.) (methanol-ethyl acetate).
  • Example 14 The title compound was prepared from the product of Example 14 (284mg, 0.81mmol) according to the method of Example 7 as a foam (86mg, 26%).
  • 1,4-Dichloro-2-butyne (0.071ml) and potassium carbonate (65mg) were stirred with anhydrous N'N'-dimethylformamide (2ml) under nitrogen atmosphere.
  • the reaction was heated to 50°C, and the product of Example 18 (63mg) was added dropwise as a solution in N'N'-dimethylformamide. After 3 hours, the reaction mixture was dispersed between water and ethyl acetate. The aqueous layer was extracted with ethyl acetate (2x). The combined organic layers were washed with brine, dried (MgSO 4 ) and the solvent evaporated to afford a yellow oil. Purification on flash silica, eluting with 10-20% ethyl acetate in hexane afforded the title compound as a colourless oil (60mg).
  • step (a) above 60mg was dissolved in dimethyl sulphoxide (3ml) and sodium azide (10mg) was added and stirred at room temperature for 3 hours.
  • the reaction mixture was dispersed between ammonium chloride/ethyl acetate (4:1).
  • the organic layer was washed with water, brine, dried (MgSO 4 ) and evaporated in vacuo to afford the title compound (55mg).
  • step (b) The azide of step (b) (60mg) was dissolved in dioxane (2ml) and cooled to 0°C under a blanket of nitrogen in a sealed tube. Dimethylamine (2ml) was condensed into the solution and the tube was sealed tightly. The sealed tube was heated at 60°C for 6 hours. By TLC (5% methanol in dichloromethane) no starting material remained. The solvent was removed in vacuo to afford a brown oil. This was purified by flash chromatography eluting with 5% methanol; 0.2% ammonia in dichloromethane to give the title compound. 1 H NMR (360MHz.
  • Example 29 The title compound of Example 29 was debenzylated according to the method of Example 5.
  • the hydrochloride salt recrystallised from ethyl acetate.
  • 1 H NMR (360MHz, d 6 -DMSO HCl salt) ⁇ 0.81-0.89 (1H, m), 1.00-1.10 (1H, m), 1.21-1.26 (1H, m), 1.36-1.55 (2H, m), 2.19-2.32 (1H, m), 3.04-3.11 (1H, m), 3.33 (6H, s), 3.90-4.15 (4H, m), 4.51 (1H, s). 6.80-6.86 (1H, m), 7.03-7.05 (1H, m), 7.18-7.28 (2H, m), 7.35-7.41 (2H. m), 7.63-7.71 (2H, m).
  • Example 30 Using the same chemistry as described in Example 22 the product of Example 30 (0.21g) was reacted to give the title compound (90mg). MS CI + m/z 550 (M+1 + , 100%); 1 H NMR (360MHz, CDCl 3 ) ⁇ 1.18-1.34 (3H, m), 1.41-1.49 (1H, m), 2.15-2.20 (6H, s), 2.24-2.38 (1H, m), 2.52-2.62 (1H, m), 2.88-2.94 (1H, m), 3.01-3.07 (1H, m), 3.20-3.26 (2H, m), 3.37-3.47 (2H, m), 3.63-3.74 (2H, m), 3.83-3.92 (1H. m), 4.01-4.16 (2H, m), 6.68-6.75 (1H, m), 6.96-7.12 (7H, m).
  • Example 1 The following Examples (Table 1) were prepared according to the method of Example 9 from (2R,3S)-(4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-spiro[5.4]dec-9-en-9-yl) trifluoromethanesulfonate (Description 14) and the appropriate phenylboronic acid.
  • Example 2 The following Examples (Table 2) were prepared according to the method of Example 22 from the corresponding Example from Table 1.
  • step (a) The compound of step (a) (266mg, 0.59mmol) in benzene:ethanol (1:1, 10ml) was hydrogenated under one atmosphere of hydrogen for 18 hours with Wilkinson's catalyst (50mg).
  • the reaction mixture was filtered through hyfloTM, concentrated to a crude oil (361mg) and purified by flash silica gel chromatography eluting with 6:1 hexane:ethyl acetate to yield the title compound as an oil (236mg, 88%).
  • step (a) The product of step (a) was dissolved in methanol/HCl (15ml) and stirred at room temperature for 21 ⁇ 2 hours. The reaction was concentrated in vacuo. and the residue triturated with ether (x5) to yield the title compound as a pale yellow solid (45mg).
  • Example 42 The product of Example 42 (200mg), benzyl bromide (70 ⁇ l) and potassium carbonate (220mg) were suspended in dimethylformamide (2ml) and the mixture was heated to 60°C for 2 hours. The mixture was cooled and diluted with water (30ml) and ethyl acetate (20ml). The organic layer was separated, washed with brine, dried (MgSO 4 ) and evaporated. The residue was purified by chromatography on silica using 10-20% ethyl acetate in hexane as eluant to give the title compound as a white solid.
  • Example 10 To a solution of the product of Example 10 (160mg, 0.47mmol), pyrrolidine acetic acid (92mg, 0.56mmol), and triethylamine (78 ⁇ l, 0.56mmol) in dry dimethylformamide (3ml) was added hydroxy benzotriazole trihydrate (HOBT: 65mg, 0.49mmol) then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (WSCDI; 91mg, 0.49mmol). The reaction mixture was stirred at room temperature for 72 hours, diluted with water, then extracted with ethyl acetate (3x).
  • HOBT hydroxy benzotriazole trihydrate
  • WSCDI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Claims (31)

  1. Eine Verbindung der Formel (I):
    Figure 01050001
    worin
    R1 Wasserstoff, Halogen, C1-6-Alkyl, C2-6-Alkenyl, C2-6-Alkinyl, C3-7-Cycloalkyl, C3-7-Cycloalkyl-C1-4-alkyl, C1-6-Alkoxy, Fluor-C1-6-alkyl, Fluor-C1-6-alkoxy, C1-4-Alkyl, substituiert durch eine C1-4-Alkoxy- oder Hydroxygruppe, Hydroxy, Trimethylsilyl, Nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONRaRb, NRaRb, SO2NRaRb oder OC1-4-Alkyl-NRaRb ist, wobei Ra und Rb jeweils unabhängig Wasserstoff oder C1-4-Alkyl sind;
    R2 und R3 jeweils unabhängig Wasserstoff, Halogen, C1-6-Alkyl, C1-6-Alkoxy, substituiert durch C1-4-Alkoxy, oder Trifluormethyl sind;
    oder, wenn R1 und R2 an benachbarte Kohlenstoffatome gebunden sind, sie so verbunden werden können, daß, zusammen mit den Kohlenstoffatomen, an die sie gebunden sind, ein 5- oder 6gliedriger Ring gebildet wird, der gegebenenfalls 1 oder 2 Heteroatome, ausgewählt aus Sauerstoff, Schwefel oder Stickstoff, oder 1 oder 2 Gruppen, ausgewählt aus S(O), S(O)2 und NRa, enthält, wobei der Ring auch 1 oder 2 Doppelbindungen enthalten kann und Ra wie zuvor definiert ist;
    R4 Wasserstoff, Halogen, C1-6-Alkyl, C2-6-Alkenyl, C2-6-Alkinyl, C3-7-Cycloalkyl, C3-7-Cycloalkyl-C1-4-alkyl, C1-6-Alkoxy, C1-4-Alkyl, substituiert durch eine C1-4-Alkoxygruppe, Trifluormethyl, Nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONRaRb bedeutet, wobei Ra und Rb wie zuvor definiert sind;
    R5 Wasserstoff, Halogen, C1-6-Alkyl, C1-6-Alkoxy, substituiert durch C1-4-Alkoxy, oder Trifluormethyl bedeutet;
    R6 bedeutet Wasserstoff, CORa, CO2Ra, COCONRaRb, COCO2Ra, C1-6-Alkyl, das gegebenenfalls substituiert ist durch eine Gruppe, ausgewählt aus (CO2Ra, CONRaRb, Hydroxy, CN, CORa, NRaRb, C(NOH)NRaRb, CONH-Phenyl(C1-4-alkyl), COCO2Ra, CONHNRaRb, C(S)NRaRb,CONRaC1-6-Alkyl-R12, CONR13-C2-6-Alkenyl, CONR13-C2-6-Alkinyl, COCONRaRb, CONRaC(NRb)NRaRb, CONRa-Heteroaryl und Phenyl, gegebenenfalls substituiert durch ein, zwei oder drei Substituenten, ausgewählt aus C1-6-Alkyl, C1-6-Alkoxy, Halogen und Trifluormethyl), oder C1-6-Alkyl, gegebenenfalls substituiert durch Oxo, substituiert durch einen 5-oder 6gliedrigen heterocyclischen Ring, der 2 oder 3 stickstoffatome enthält, gegebenenfalls substituiert durch =O oder =S und gegebenenfalls substituiert durch eine Gruppe der Formel ZNR7R8, worin
    Z C1-6-Alkylen oder C3-6-cycloalkyl ist;
    R7 Wasserstoff oder C1-4-Alkyl, C3-7-Cycloalkyl, C3-7-Cycloalkyl-C1-4-alkyl oder C2-4-Alkyl, substituiert durch C1-4-Alkoxy oder Hydroxyl, ist;
    R8 Wasserstoff oder C1-4-Alkyl, C3-7-Cycloalkyl, C3-7-Cycloalkyl-C1-4-alkyl oder C2-4-Alkyl, substituiert durch C1-4-Alkoxy, Hydroxyl oder einen 4-, 5- oder 6gliedrigen heteroaliphatischen Ring, der ein oder zwei Heteroatome, ausgewählt aus N, O und S, enthält, ist;
    oder R7, R8 und das Stickstoffatom, an das sie gebunden sind, einen heteroaliphatischen Ring mit 4 bis 7 Ringatomen bilden, gegebenenfalls substituiert durch ein oder zwei Gruppen, ausgewählt aus Hydroxy oder C1-4-Alkoxy, gegebenenfalls substituiert durch eine C1-4-Alkoxy- oder Hydroxylgruppe, und gegebenenfalls enthaltend eine Doppelbindung, wobei der Ring gegebenenfalls ein Sauerstoff- oder Schwefel-Ringatom, eine Gruppe S(O) oder S(O)2 oder ein zweites Stickstoffatom enthalten kann, das Teil eines NH- oder NRc-Restes sein wird, wobei Rc C1-4-Alkyl ist, das gegebenenfalls durch Hydroxy oder C1-4-Alkoxy substituiert ist;
    oder R7, R8 und das Stickstoffatom, an das sie gebunden sind, ein nichtaromatisches azabicyclisches Ringsystem mit 6 bis 12 Ringatomen bilden;
    oder Z, R7 und das Stickstoffatom, an das sie gebunden sind, einen heteroaliphatischen Ring mit 4 bis 7 Ringatomen bilden, der gegebenenfalls ein Sauerstoff-Ringatom enthalten kann;
    R9a und R9b jeweils unabhängig Wasserstoff oder C1-4-Alkyl bedeuten oder R9a und R9b derart verbunden sind, daß, zusammen mit den Kohlenstoffatomen, an die sie gebunden sind, ein C5-7-Ring gebildet wird;
    R12 ORa, CONRaRb oder Heteroaryl bedeutet;
    R13 H oder C1-6-Alkyl bedeutet;
    m null, 1, 2 oder 3 ist; und
    n null, 1, 2 oder 3 ist, mit der Maßgabe, daß die Gesamtsumme von m und n 2 oder 3 ist;
    oder ein pharmazeutisch annehmbares Salz davon.
  2. Eine wie in Anspruch 1 beanspruchte Verbindung der Formel (Ia) oder ein pharmazeutisch annehmbares Salz davon:
    Figure 01070001
    worin R1, R2, R3, R4, R5, m und n wie in Anspruch 1 definiert sind, und Q1 CH, N oder C-ZNR7R8 ist, wobei Z, R7 und R8 wie in Anspruch 1 definiert sind.
  3. Eine wie in Anspruch 1 beanspruchte Verbindung der Formel (Ib) oder ein pharmazeutisch annehmbares Salz davon:
    Figure 01080001
    worin R1, R2, R3, R4, R5, m und n wie in Anspruch 1 definiert sind, Q2 CH oder N ist, und Z, R7 und R8 wie in Anspruch 1 definiert sind.
  4. Eine wie in Anspruch 1 beanspruchte Verbindung der Formel (Ic) oder ein pharmazeutisch annehmbares Salz davon:
    Figure 01080002
    worin R6 wie in Anspruch 1 definiert ist;
    A1 C1-4-Alkoxy ist;
    A2 Wasserstoff, Halogen, C1-4-Alkyl oder Fluor-C1-4-alkyl ist; und
    A3 Wasserstoff oder Halogen ist.
  5. Eine wie in Anspruch 1 beanspruchte Verbindung der Formel (Id) oder ein pharmazeutisch annehmbares Salz davon
    Figure 01090001
    worin R1, R2, R3, R5, R5, R6, R9a, R9b, m und n wie in Anspruch 1 definiert sind.
  6. Eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung, worin R1 Wasserstoff, C1-4-Alkyl, C1-4-Alkoxy, Halogen oder CF3 ist.
  7. Eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung, worin R2 Wasserstoff, C1-4-Alkyl, C1-4-Alkoxy, Halogen oder CF3 ist.
  8. Eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung, worin R3 Wasserstoff, Fluor, Chlor oder CF3 ist.
  9. Eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung, worin R4 Wasserstoff ist.
  10. Eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung, worin R5 Wasserstoff, Fluor, Chlor oder CF3 ist.
  11. Eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung, worin n 1 ist.
  12. Eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung, worin m 1 oder 2 ist.
  13. Eine wie in irgendeinem der Ansprüche 1 bis 12 beanspruchte Verbindung, worin R6 C1-6-Alkyl ist, substituiert durch einen 5gliedrigen heterocyclischen Ring, der 2 oder 3 stickstoffatome enthält, wobei der Ring gegebenenfalls durch =O oder =S substituiert ist und der Ring gegebenenfalls durch eine Gruppe der Formel ZNR7R8 substituiert ist, wobei Z, R7 und R8 wie in Anspruch 1 definiert sind.
  14. Eine wie in Anspruch 13 beanspruchte Verbindung, worin der heterocyclische Ring ausgewählt ist aus:
    Figure 01100001
    Figure 01100002
    Figure 01100003
  15. Eine wie in Anspruch 14 beanspruchte Verbindung, worin der heterocyclische Ring ausgewählt ist aus:
    Figure 01110001
    Figure 01110002
  16. Eine wie in irgendeinem der Ansprüche 1 bis 15 beanspruchte Verbindung, worin Z CH2 ist.
  17. Eine wie in irgendeinem der Ansprüche 1 bis 16 beanspruchte Verbindung, worin R7 eine C1-4-Alkylgruppe oder eine C2-4-Alkylgruppe, die durch eine Hydroxyl- oder C1-2-Alkoxygruppe substituiert ist, ist, R8 eine C1-4-Alkylgruppe oder eine C1-4-Alkylgruppe, die durch eine Hydroxyl- oder C1-2-Alkoxygruppe substituiert ist, ist, oder R7 und R8 derart verbunden sind, daß sie, zusammen mit dem Stickstoffatom, an das sie gebunden sind, eine Azetidinyl-, Pyrrolidinyl-, Piperidyl-, Morpholino-, Thiomorpholino-, Piperazinogruppe oder eine am Stickstoffatom durch eine C1-4-Alkylgruppe oder eine C2-4-Alkylgruppe, substituiert durch eine Hydroxy- oder C1-2-Alkoxygruppe, substituierte Piperazinogruppe bilden.
  18. Eine wie in irgendeinem der Ansprüche 1 bis 17 beanspruchte Verbindung, worin Z CH2 ist und NR7R8 Dimethylamino, Azetidinyl oder Pyrrolidino ist.
  19. Eine Verbindung, ausgewählt aus:
    (2S,3S,9R)-4-Aza-1,7-dioxa-3,9-diphenylspiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-3,9-diphenylspiro[5.5]undecan,
    (2R,3S,9S)-4-Aza-4-benzyl-1,7-dioxa-3,9-diphenylspiro[5.5]undecan,
    (2R,3S,9R)-4-Aza-4-benzyl-1,7-dioxa-3,9-diphenylspiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-3,9-diphenylspiro[5.5]undecan-4-ylmethyl)-2,4-dihydro-1,2,4-triazol-3-on,
    4-Aza-4-benzyl-1,7-dioxa-3,8-diphenylspiro[5.4]decan,
    oder ein pharmazeutisch annehmbares Salz davon.
  20. Eine Verbindung, ausgewählt aus:
    (2S,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-phenylspiro[5.4]decan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-methoxyphenyl)spiro[5.4]decan,
    (2R,3S,8R)-4-Aza-4-benzyl-1,7-dioxa-3-(4-fluorphenyl)-8-phenylspiro[5.4]decan,
    (2R,3S,8S)-4-Aza-4-benzyl-1,7-dioxa-3-(4-fluorphenyl)-8-phenylspiro[5.4]decan,
    (2R,3S,8R)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-8-phenylspiro[5.4]decan,
    (2R,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-8-phenylspiro[5.4]decan,
    (2R,3S,8R)-4-Aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorphenyl)-8-phenylspiro[5.4]decan,
    (2R,3S,8S)-4-Aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorphenyl)-8-phenylspiro[5.4]decan,
    4-Aza-4-benzyl-7-dioxa-5-phenyl-9-(2-trifluormethylphenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-trifluormethylphenyl)spiro[5.5]undecan,
    (2R,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-trifluormethylphenyl)spiro[5.5]undecan,
    (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2S,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-4-(5-(dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorphenyl)-9-(2-(trifluormethyl)phenyl)spiro[5.5]undecan,
    4-Aza-4-benzyl-1,7-dioxa-3-(4-fluorphenyl)-9-(3-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2R,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(3-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(3-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2S,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(3-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(3-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-4-(5-(dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorphenyl)-9-(3-(trifluormethyl)phenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-4-benzyl-7-dioxa-5-phenyl-9-(2-(trifluormethoxy)phenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-(trifluormethoxy)phenyl)spiro[5.5]undecan,
    4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-(trifluormethoxy)phenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-4-(5-(dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorphenyl)-9-(2-(trifluormethoxy)phenyl)spiro[5.5]undecan,
    (2S,3S,9S)-4-Aza-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7dioxa-3-(4-fluorphenyl)-9-(3-(trifluormethyl)phenyl)spiro[4.5]decan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-3-(4-fluorphenyl)-9-(2-naphthyl)spiro[5.4]decan,
    (2S,3S,9S)-4-Aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorphenyl)-9-(2-naphthyl)spiro[5.4]decan,
    (2S,3S,9S)-4-Aza-4-benzyl-1,7-dioxa-3-(4-fluorphenyl)-9-(2-thio-methylphenyl)spiro[5.4]decan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-9-(5-fluor-2-methoxyphenyl)-3-(4-fluorphenyl)-4-(1,3-imidazol-4-ylmethyl)spiro[5.4]decan,
    (2S,3S,9S)-4-Aza-1,7-dioxa-9-(5-fluor-2-isopropoxyphenyl)-3-(4-fluorphenyl)-4-(1,3-imidazol-4-ylmethyl)spiro[5.4]decan,
    (2S,3S,9S)-4-Aza-4-benzyl-9-(2,5-dimethoxyphenyl)-1,7-dioxa-3-(4-fluorphenyl)spiro[5.4]decan,
    (2S,3S,9S)-4-Aza-4-(carbonylmethylpyrrolidin-1-yl)-1,7-dioxa-3-(4-fluorphenyl)spiro[5.4]decan,
    oder ein pharmazeutisch annehmbares Salz davon.
  21. Eine Verbindung der Formel
    Figure 01140001
    ausgewählt aus den Verbindungen, worin R1, R2 und R3 die folgenden Definitionen einnehmen: Bsp.-Nr. R1 R2 R3 33 3'-CF3 H H 34 2'-CF3 H H 35 4'-OCH3 H H 36 2'-CH3 H H 37 2'-OCF3 H H 38 3'-OCH3 H H 39 3'-NH2 H H 40 3'-OCH(CH3)2 H H 41 2'-OCH3 5'-F H 42 2'-OCH3 5'-OCH3 H 43 2'-OCH(CH3 )2 H H 44 2'-O(CH2)2CH3 H H 45 2'-OCH(CH3)2 5'-F H 46 2'-OCH(CH3)2 5'-CH(CH3)2 H 47 2'-OCH3 5'-CH(CH3)2 H 48 2'-OCH2CH3 5'-F H 49 2'-OCH3 5'-C(CH3)3 H 50 2'-OH H H 51    2'-OCH2 CH2 -3' H 52 2'-OCH3 6'-F H 53 2'-CH3 3'-F H 54 3'-CH3 5'-CH3 H 55 2'-OCH3 3'-OCH3 H 56 2'-C(O)N(CH2CH3)2 H H 57 2'-OCH(CH3)2 4'-F 5'-F 58 2'-S(O)2N(CH2CH3)2 H H 59    2'-NH-(CH2)3-3' H 60 2'-F 5'-F H 61    2'-O-CH2-O-3' H 62 2'-OCH3 5'-CF3 H 63 2'-OCH(CH3)2 4'-F H 64    2'-O-(CH2)3-3' 5'-F 65 2'-CH2OH H H 66 2'-OCH(CH3)2 5-CF3 H 67 2'-CH3 5'-F H 68 2'-OCH2CHF2 5'-F H 69 2'-OCH2CH2N(CH3)2 5'-F H 70 2'-OCH2CH2F 5'-F H
    oder ein pharmazeutisch annehmbares Salz davon.
  22. Eine Verbindung der Formel
    Figure 01160001
    ausgewählt aus den Verbindungen, worin R1 und R2 die folgenden Definitionen einnehmen: Bsp.-Nr. R1 R2 71 OCH3 H 72 OCF3 H 73 OCH(CH3)2 5'-F 74 OCH3 5'-CH(CH3)2 75 OCH2CH3 5'-F 76 OCH2CH2CH3 H 77 OCH3 5'-CF3 78 OCH(CH3)2 4'-F,
    oder ein pharmazeutisch annehmbares Salz davon.
  23. Eine wie im irgendeinem vorhergehenden Anspruch beanspruchte Verbindung zur Verwendung in der Therapie.
  24. Eine pharmazeutische Zusammensetzung, die eine wie in irgendeinem der Ansprüche 1 bis 22 beanspruchte Verbindung in Verbindung mit einem pharmazeutisch annehmbaren Träger oder Hilfsstoff enthält.
  25. Die Verwendung einer wie in irgendeinem der Ansprüche 1 bis 22 beanspruchten Verbindung zur Herstellung eines Medikaments zur Behandlung oder Prävention einer physiologischen Störung, die mit einem Überschuß an Tachykininen in Verbindung steht.
  26. Die Verwendung einer wie in irgendeinem der Ansprüche 1 bis 22 beanspruchten Verbindung zur Herstellung eines Medikaments zur Behandlung oder Prävention von Schmerz oder Entzündung.
  27. Die Verwendung einer wie in irgendeinem der Ansprüche 1 bis 22 beanspruchten Verbindung zur Herstellung eines Medikaments zur Behandlung oder Prävention von Migräne.
  28. Die Verwendung einer wie in irgendeinem der Ansprüche 1 bis 22 beanspruchten Verbindung zur Herstellung eines Medikaments zur Behandlung oder Prävention von Erbrechen.
  29. Die Verwendung einer wie in irgendeinem der Ansprüche 1 bis 22 beanspruchten Verbindung zur Herstellung eines Medikaments zur Behandlung oder Prävention von postherpetischer Neuralgie.
  30. Ein Verfahren zur Herstellung einer wie in Anspruch 1 beanspruchten Verbindung, welches umfaßt:
    (A), für eine Verbindung der Formel (I), bei der R6 anders ist als H, die Umsetzung einer Verbindung der Formel (II)
    Figure 01180001
    worin R1, R2, R3, R4, R5, R9a, R9b, m und n wie in Anspruch 1 definiert sind, mit einer Verbindung der Formel (III): LG-R6a worin R6a eine Gruppe der wie in Anspruch 1 definierten Formel R6 oder ein Vorläufer dafür ist und LG eine Abgangsgruppe ist; und, wenn R6a eine Vorläufergruppe ist, die Umwandlung dieser in eine Gruppe R6; oder
    (B), für eine Verbindung der Formel (I), worin R6 eine 1,2,3-Triazol-4-ylmethylgruppe bedeutet, die durch CH2NR7R8 substituiert ist, die Umsetzung einer Verbindung der Formel (IV)
    Figure 01180002
    mit einem Amin der Formel NHR7R8; oder
    (C), für eine Verbindung der Formel (I), worin R6 eine C1-6-Alkylgruppe bedeutet, die durch eine unsubstituierte oder substituierte 1,2,4-Triazolylgruppe substituiert ist, die Umsetzung eines Zwischenprodukts der Formel (II) mit einer Verbindung der Formel (V)
    Figure 01190001
    worin Hal ein Halogenatom ist, m eine ganze Zahl von 1 bis 6 ist und R18 H, CONH2 oder OCH3 ist, gefolgt, wo notwendig, von der Umwandlung in eine Verbindung der Formel (I); oder
    (D) die Herstellung aus einer Verbindung der Formel (VI)
    Figure 01190002
    durch eine säurekatalysierte intramolekulare Cyclisierungsreaktion; oder
    (E) die Herstellung durch Umwandlung einer anderen Verbindung der Formel (I); oder
    (F), für eine Verbindung der Formel (I), worin n 1 ist und m 1 ist, die Reduktion einer Verbindung der Formel (XX)
    Figure 01200001
    wobei sich an jedes Verfahren anschließt, wo notwendig, die Entfernung jeglicher Schutzgruppe, wo vorhanden,
    und, wenn die Verbindung der Formel (I) als eine Mischung aus Enantiomeren oder Diastereoisomeren erhalten wird, gegebenenfalls die Auftrennung der Mischung, um das erwünschte Enantiomer zu erhalten,
    und/oder, falls erwünscht, die Umwandlung der resultierenden Verbindung der Formel (I) oder eines Salzes davon in ein pharmazeutisch annehmbares Salz davon.
  31. Eine Verbindung der Formel (XX)
    Figure 01200002
    worin
    R1, R2, R3, R4, R5, R6, R9a und R9b wie in Anspruch 1 definiert sind, oder ein Salz davon.
EP95940382A 1994-12-23 1995-12-15 Spiroketalderivate, diese enthaltende zusammensetzungen und ihre verwendung als arzneimittel Expired - Lifetime EP0799231B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9426103 1994-12-23
GBGB9426103.9A GB9426103D0 (en) 1994-12-23 1994-12-23 Therapeutic agents
PCT/GB1995/002927 WO1996020197A1 (en) 1994-12-23 1995-12-15 Spiroketal derivatives, compositions containing them and their use as therapeutic agents

Publications (2)

Publication Number Publication Date
EP0799231A1 EP0799231A1 (de) 1997-10-08
EP0799231B1 true EP0799231B1 (de) 1999-03-17

Family

ID=10766510

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95940382A Expired - Lifetime EP0799231B1 (de) 1994-12-23 1995-12-15 Spiroketalderivate, diese enthaltende zusammensetzungen und ihre verwendung als arzneimittel

Country Status (10)

Country Link
US (1) US5728695A (de)
EP (1) EP0799231B1 (de)
JP (1) JPH10511381A (de)
AT (1) ATE177749T1 (de)
AU (1) AU698134B2 (de)
CA (1) CA2207653A1 (de)
DE (1) DE69508434T2 (de)
ES (1) ES2128791T3 (de)
GB (1) GB9426103D0 (de)
WO (1) WO1996020197A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603136D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
KR20000022060A (ko) * 1996-06-21 2000-04-25 더블유. 지. 콜 스피로-피페리딘 유도체 및 치료제로서의 이의 용도
DE69728883T2 (de) * 1996-07-17 2005-04-07 Merck & Co., Inc. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929094A (en) * 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) * 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
ES2231902T3 (es) * 1996-12-02 2005-05-16 MERCK SHARP & DOHME LTD. Uso de antagonistas del receptor de nk-1 para el tratamiento de transtornos del movimiento.
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
CA2273806A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating substance use disorders
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
CA2273351A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating sexual dysfunction
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
CA2273856A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
US20040097573A1 (en) * 1998-05-21 2004-05-20 Susan Boyce Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
IL154993A0 (en) * 2000-09-29 2003-10-31 Neurogen Corp High affinity small molecule c5a receptor modulators
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GEP20125566B (en) 2005-07-15 2012-07-10 Amr Technology Inc Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
WO2008118948A1 (en) 2007-03-26 2008-10-02 Atherogenics, Inc. Methods and compositions of derivatives of probucol for the treatment of diabetes
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
BRPI0811557A2 (pt) * 2007-05-09 2019-09-24 Salutria Pharmaceuticals Llc composto, composição farmacêutica, método de tratamento ou profilaxia de uma condição inflamatória.
EP3103791B1 (de) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino-derivate als histondeacetylase-hemmer
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU4185096A (en) 1996-07-19
EP0799231A1 (de) 1997-10-08
DE69508434T2 (de) 1999-10-14
GB9426103D0 (en) 1995-02-22
ATE177749T1 (de) 1999-04-15
JPH10511381A (ja) 1998-11-04
WO1996020197A1 (en) 1996-07-04
ES2128791T3 (es) 1999-05-16
DE69508434D1 (de) 1999-04-22
US5728695A (en) 1998-03-17
CA2207653A1 (en) 1996-07-04
AU698134B2 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
EP0799231B1 (de) Spiroketalderivate, diese enthaltende zusammensetzungen und ihre verwendung als arzneimittel
US5962485A (en) N-(2-benzyloxy-1-phenethyl)-N-(2'-methoxyethyl)amino-methane compounds are useful as tachykinin antagonists
US5985896A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU715558B2 (en) Spiro-piperidine derivatives and their use as tachykinin antagonists
AU706344B2 (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU710873B2 (en) Morpholine derivatives and their use as therapeutic agents
US6096766A (en) 3-benzylaminopiperidines as tachykinin receptor antagonists
AP495A (en) Piperidine derivatives
JP3071467B2 (ja) 置換モルホリン誘導体およびその治療剤としての使用
DE60004504T2 (de) Tetrahydropyranderivate und deren verwendung als therapeutische mittel
EP0880528B1 (de) Spiro-ketal derivate und ihre verwendung als therapeutische wirkstoffe
GB2321058A (en) Ethane-1,2-diamine derivatives and tachykinin antagonists
US6080740A (en) Spiro-ketal derivatives and their use as therapeutic agents
CA2245578A1 (en) Spiro-ketal derivatives and their use as therapeutic agents
CA2237638A1 (en) Spiro-piperidine derivatives and their use as tachykinin antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19980130

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19990317

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990317

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990317

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990317

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990317

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990317

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990317

REF Corresponds to:

Ref document number: 177749

Country of ref document: AT

Date of ref document: 19990415

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69508434

Country of ref document: DE

Date of ref document: 19990422

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2128791

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990617

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990617

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991215

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991215

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20041006

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20041217

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20050110

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050131

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051215

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060701

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20051215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060831

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20051216